Optimizing second-line therapy for chronic myeloid leukemia.
Indian J Cancer
;
2012 Jan-Mar; 49(1): 46-56
Artigo
em Inglês
| IMSEAR
| ID: sea-144551
ABSTRACT
Treatment of chronic myeloid leukemia has evolved from symptom control to long-term disease-free survival with cure potentially round the corner. This required faster, deeper, and longer response. Optimizing treatment decisions therefore requires clear understanding of and strict implementation of guidelines for shift from imatinib. In patients who are resistant to or intolerant of imatinib, second-line TKIs have to be selected carefully. Currently available data show comparable efficacy between nilotinib and dasatinib. With a better safety profile (especially with respect to grade 3 or 4 hematologic toxicity and clinically relevant non-hematologic toxicities), nilotinib becomes the preferred choice in most instances.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Piperazinas
/
Pirimidinas
/
Tiazóis
/
Proteínas Tirosina Quinases
/
Humanos
/
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
Aberrações Cromossômicas
/
Proteínas de Fusão bcr-abl
/
Resultado do Tratamento
/
Intervalo Livre de Doença
Tipo de estudo:
Guia de Prática Clínica
/
Estudo prognóstico
Idioma:
Inglês
Revista:
Indian J Cancer
Ano de publicação:
2012
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS